Politiparty
Politiparty

118th Congress Health

S. 1522: To require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable

A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.

Introduced

  1. Introduced (completed)May 10, 2023
  2. Passed Senate (not reached)
  3. Passed House (not reached)
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Introduced in Senate, May 10, 2023

This bill requires the Food and Drug Administration to report on its designation of biosimilars as interchangeable, including the applicable standards, authorities, evidence, and other factors involved in such designations. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Who scored on this bill

0 points earned

No member has earned points from it yet.

See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by Roger Marshall

History

  1. May 10, 2023Introduced in the Senate by Roger Marshall.
Show the full action history (2 actions)
  1. May 10, 2023Introduced in Senate
  2. May 10, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.